Cargando…
Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition
Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of cancer, but the strategies employed have continued to evolve. Recently, much clinical focus has been on combining targeted therapies with ICI for the purpose of manipulating...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523960/ https://www.ncbi.nlm.nih.gov/pubmed/36175961 http://dx.doi.org/10.1186/s12943-022-01656-z |